Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AL002 in Healthy Adults and Alzheimer's Disease
NCT03635047Phase 1Completed
- Sponsor
- Alector
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing AL002 with Placebo (2 arms). Primary endpoint: Number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs) at 141 days. Started Nov 2018; status: completed.
02
Drugs
AL002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03635047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635047.